⁶⁸Ga-FAPI PET/CT in cardiac Anderson–Fabry disease: novel insights into disease assessment from a case series
Year: 2026
Type: article
Study design: Case Report
Abstract: Anderson-Fabry disease (AFD) is an X-linked lysosomal disorder in which cardiac involvement is the main cause of morbidity and mortality, manifesting as left ventricular hypertrophy, heart failure, arrhythmias, and myocardial fibrosis. Myocardial fibrosis is a key pathophysiological process associated with an adverse prognosis. While cardiac magnetic resonance (CMR) identifies established myocardial fibrosis, fibroblast activation protein inhibitor (FAPI) PET enables the molecular assessment of FAP-associated activity. By complementing conventional CMR parameters, including late gadolinium enhancement and native T1 mapping, FAPI PET may improve the characterization and phenotypic classification of cardiac involvement in Anderson-Fabry disease. We report three cases of AFD patients, who underwent Gallium-68-fibroblast activation protein inhibitor (⁶⁸Ga-FAPI) PET-CT as part of a prospective study designed to assess myocardial fibrosis. Overall, ⁶⁸Ga-FAPI uptake closely correlated with CMR findings, reinforcing the role of cardiac fibroblast activation as a relevant pathogenic mechanism in AFD. These findings highlight this new molecular imaging as a promising tool for early detection, risk stratification, and therapeutic guidance in AFD.
Source: EJNMMI Reports
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7236764845
